Navigation Links
PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
Date:12/7/2012

Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchang
'/>"/>
SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GenWay Biotech Appoints New Vice President of Custom/OEM
2. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
5. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
6. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
7. Obamacare Ruling, Other Pivotal News Rocks Biotech Sector in June
8. Tougher Times May be Ahead for Biotechs: 1H12 Fundraising Slows
9. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
10. Early Birds Save Up to $600 on Asian Biotech and Pharmaceutical Conferences
11. Lifeline Biotechnologies First Warning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... JOLLA, Calif. , July 28, 2015   ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 4, 2015, at 5:00 pm Eastern Daylight Time to ...
(Date:7/28/2015)... 2015 On the afternoon of August 11, ... CPI International, Inc. (CPI), plans to file its Form ... with the Securities and Exchange Commission and to issue ...  At 11 a.m. (EDT) on Wednesday, August 12, 2015, ... with this release that will be Web cast simultaneously ...
(Date:7/28/2015)... 2015 A German Diabetes Center clinical study ... probiotic enriches human gut microbiota and modifies gut ... study involved daily administration of Nutraceutix,s L. reuteri ... patented BIO- tract ® delivery technology that ... their way to the intestinal tract. The ...
Breaking Medicine Technology:Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 3CPI International To Announce Third Quarter 2015 Financial Results 2Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism 2
... International Myeloma Workshop held in,Kos, Greece ... with bortezomib, dexamethasone and lenalidomide plus,dexamethasone, ... as a single agent in patients ... 29, 2007 /PRNewswire-FirstCall/ -- Keryx,Biopharmaceuticals, Inc. ...
... 2007--A cervical cancer vaccine has shown 90%,efficacy for prevention ... papillomavirus (HPV) types targeted by,the vaccine, conclude authors of ... of The Lancet., HPV types 16 and 18 account ... there are up to 15,oncogenic HPV types which can ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7Vaccine Can Prevent Cervical Cancer and Precancerous Lesions 2
(Date:7/29/2015)... , ... July 29, 2015 , ... July is National UV Awareness Month, and in ... DC shares tips on how to protect skin from the sun, as well as how ... cancer, and is one of the most common skin conditions in America. Many people do ...
(Date:7/29/2015)... ... , ... A June 10, 2015 article from the News-Press, entitled " It's ... having regular skin cancer screenings from an early age. Skin cancer can strike at ... early, skin cancer is rarely fatal; however, if left alone for too long, the ...
(Date:7/29/2015)... ... 29, 2015 , ... Employee Fiduciary, LLC announces the launch of its new, ... types of plans administered, years in business, and credentials of all Employee Fiduciary financial ... plan with Employee Fiduciary. A search can be done by zip code so a ...
(Date:7/29/2015)... ... July 29, 2015 , ... Several years ago, in order to ... autism, Little City took a proactive stance and began planning the Children’s Village consisting ... provides valuable support to building the third home. , “We are very pleased to ...
(Date:7/29/2015)... ... , ... Attorneys representing American families in national talcum powder lawsuits announce the ... a page dedicated to news related to pending talcum powder lawsuits, as well as ... News page was launched with eight initial articles. , “We decided to add ...
Breaking Medicine News(10 mins):Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Employee Fiduciary Launches Financial Advisor Directory 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 2Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 3
... the number of influenza cases over the last four months ... statistics released by the Public// Health Agency on Dec 16. ... March or early April and the Calgary Health Region monitors ... A are; sudden headaches and fever, dry coughs and aching ...
... Ruth A. Kleinerman and his colleagues quantifies the risk ... tissue sarcomas and finds that// this risk persists for ... ,The findings published in the January 3 issue of ... importance of regular medical surveillance for these patients, the ...
... on ailments related to stomach like diarrhoea, food poisoning ... NHS Direct this festive season. NHS Direct is// a ... contacted on 0845 46 47. ,Stomach ache, ... calls received during the festive period. ,NHS ...
... U.S. Centers for Disease Control and Prevention (CDC) shows that ... ,The CDC defines binge drinking as "a common ... Alcohol Abuse and Alcoholism defines binge drinking as a pattern ... at least 0.08 percent. ,Binge drinking is now ...
... a busy man today; fielding complaints from the public, a ... taken to court, from an NGO.// ,The yoga ... hold the key to curing AIDS by performing yoga and ... earlier rubbished these statements, saying while he supported the practice ...
... A British doctor of Indian origin and his colleague are ... a challenge to the monopoly of multinational drug companies. ... and Steve Brocchini from the London School of Pharmacy are ... C. ,The two academics have devised a way ...
Cached Medicine News:Health News:Risk Of Soft Tissue Sarcomas In Hereditary Retinoblastoma Survivors 2Health News:Risk Of Soft Tissue Sarcomas In Hereditary Retinoblastoma Survivors 3Health News:NRI Doctor's R&D Model in India to Slash Cost of Drugs 2
... 3000 Plus Sectioning System provides a versatile ... or plant tissues. The 3000 employs ... without freezing or embedding. The creation ... destruction of enzyme activities, and other deleterious ...
... Vibratome comes standard with a square ... blocks are utilized for mounting specimens ... vice. The blocks are annodized ... can be reused. They are ...
Injector blades come ten to an injector and allow for the easy replacement of Vibratome cutting blades....
... Works includes everything from the care ... fuse, Spare Fluorescent Bulb, additional Vibratome ... Blocks, and a Specimen Tray. ... stage, 1/2" speciment mounts, replacement rotating ...
Medicine Products: